



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

September 13, 2022

Eliot Forster  
CEO  
F-star Therapeutics, Inc.  
Eddeva B920 Babraham Research Campus  
Cambridge, United Kingdom CB22 3AT

**Re: F-star Therapeutics, Inc.**  
**Form 10-K for the year ended December 31, 2021**  
**File Number 1-37718**

Dear Mr. Forster:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences